Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Accustem Sciences Q3 2026 Results: Net Loss of $1.87M, Loss Widens

Accustem Sciences Inc. reported a net loss of $2,608,351 for the nine months ended September 30, 2026, significantly higher than the $1,241,708 loss in the prior year period, primarily due to a $1.5 million acquired in-process research and development expense. The company faces substantial liquidity concerns with a working capital deficit of $5,980,129 and continues to rely on related party financing to fund its clinical-stage diagnostic operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.9-0.4
EPS (diluted, $ a share)$-0.12$-0.02

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: ACUT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Accustem Sciences Inc.: key numbers

Share price
$0.1180Close, Nov 20
Market cap
$1.9M
Shares outstanding
16.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.